Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:48:52.561Z.
Calculation as of: 2026-10-06T19:48:52.561Z.
Quote observation: 2026-10-06T19:45:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$9.63B
Price/OCF Ratio
35.36
TTM Avg
39.12
3Y Avg
42.86
5Y Avg
42.86
Market Cap
$9.85B
Price/OCF Ratio
73.01
TTM Avg
63.86
3Y Avg
60.00
5Y Avg
71.03
Market Cap
$9.92B
Price/OCF Ratio
20.13
TTM Avg
16.46
3Y Avg
19.80
5Y Avg
26.88
Market Cap
$10.00B
Price/OCF Ratio
16.43
TTM Avg
19.74
3Y Avg
20.95
5Y Avg
19.39
Market Cap
$8.95B
Price/OCF Ratio
47.02
TTM Avg
431.84
3Y Avg
416.88
5Y Avg
416.88
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.49B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 35.36 | 39.12 | 42.86 | 42.86 |
| Henry Schein, Inc. (HSIC)vs › | $9.63B | 13.76 | 15.40 | 14.44 | 15.10 |
| Insulet Corp. (PODD)vs › | $9.31B | 18.21 | 28.05 | 52.68 | 114.81 |
| Bruker Corporation (BRKR)vs › | $9.24B | 48.51 | 56.23 | 39.18 | 38.23 |
| Repligen Corporation (RGEN)vs › | $9.85B | 73.01 | 63.86 | 60.00 | 71.03 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.92B | 20.13 | 16.46 | 19.80 | 26.88 |
| The Ensign Group, Inc. (ENSG)vs › | $10.00B | 16.43 | 19.74 | 20.95 | 19.39 |
| Bruker Corporation (BRKRP)vs › | $8.95B | 47.02 | 431.84 | 416.88 | 416.88 |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.94B | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
